Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 7/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 3/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15116633 | 1.00 | CA1 (0.40) | CA1CA2CA7CTSLCTSK | |
| SCHEMBL14899075 | 0.92 | CA1 (0.37) | CA1CA2CA7CTSLCTSK | |
| SCHEMBL15105955 | 0.86 | CA1 (0.40) | CA1CA2CA7CTSLCTSK | |
| SCHEMBL2377936 | 0.86 | CA1 (0.40) | CA1CA2CA7CTSLCTSK | |
| SCHEMBL2377942 | 0.86 | CA1 (0.40) | CA1CA2CA7CTSLCTSK | |
| SCHEMBL15125118 | 0.85 | CA1 (0.39) | CA1CA2CA7CTSLCTSK | |
| SCHEMBL17191511 | 0.83 | CA1 (0.41) | CA1CA2CA7CTSLCTSK | |
| SCHEMBL15113655 | 0.83 | CA1 (0.41) | CA1CA2CA7CTSLCTSK | |
| SCHEMBL1480407 | 0.81 | CA1 (0.39) | CA1CA2CA7CTSLCTSK | |
| SCHEMBL15105800 | 0.81 | CA1 (0.39) | CA1CA2CA7CTSLCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3019196-B1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-2802326-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-04-18 | — | — | EP | disclosed |